
Jumi Yi, MD\textsuperscript{1}, Robert Lou\textsuperscript{2}, Jamie Bricoll\textsuperscript{1}, Ray Widen, PhD\textsuperscript{3}, Suzane Silbert, PhD\textsuperscript{3}, Levy Mahoro\textsuperscript{2}, and Robert C. Jerris, PhD\textsuperscript{1,2}

\textsuperscript{1} Emory University School of Medicine, \textsuperscript{2} Children’s Healthcare of Atlanta, \textsuperscript{3} Tampa General Hospital

Introduction

Rapid, accurate diagnostic modalities for carbapenemase producing organisms (CPO) detection are needed. Matrix-Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-TOF MS) has been shown to accurately and quickly identify CPOs compared to traditional methods. In this study, we hypothesized that MALDI-TOF MS would accurately identify CPO with the following known mechanisms of resistance: KPC, VIM, NDM, IMI, IMP, OXA-48, and GES-16.

Methods

35 CPO, 3 beta-lactamases (GES-5, CMY-2, SHV-type ESBL) and 76 other non-carbapenemase producing organisms (nCPO) with no other known mechanisms of resistance were tested for carbapenemase production with microdilution, Etest\textsuperscript{®}, and MALDI-TOF MS. Degradation of any ertapenem specific peak (476 [M + H]\textsuperscript{+}, 498 [M+ Na]\textsuperscript{+}, and 520 [M + 2 Na]\textsuperscript{+}) on MALDI-TOF MS was considered consistent with a CPO. MALDI-TOF MS results were compared to Etest\textsuperscript{®}, modified Hodge test, and microdilution (MicroScan [Beckman-Coulter] or Phoenix [Becton Dickinson]).

Results

All of the 76 nCPO had intact ertapenem peaks on MALDI-TOF MS. 2 of the nCPO, SHV-type ESBL \textit{K.pneumoniae} and CMY-2 \textit{C.freundii}, showed ertapenem degradation on MHT. 54.3\% (19/35) of CPO
Antibiotic Resistance Center Seminar Abstract Submission

demonstrated degradation of all three ertapenem specific peaks on MALDI-TOF MS. 94.2% (33/35) of CPO demonstrated the absence of at least one peak. MHT identified 100% of CPOs but was also positive for 2/3 beta-lactamase producing nCPO. Microdilution of ertapenem, imipenem, and meropenem identified 94.3%, 97.1%, and 91.4% of CPOs, respectively. KPC-4 *K. pneumoniae* and IMP-18 *Ps. aeruginosa* were detected by MHT but not MALDI-TOF MS. Additional kinetic studies and sequence analysis are planned for these isolates. 1 of 3 KPC *E. cloacae* was not identified by MHT or microdilution and there was only degradation at the 520 peak on MALDI-TOF MS. Specificity of our assay was 100%.

**Discussion**

CPO detection is difficult and may require multiple methods for accurate detection. No method of detection identified all CPOs. MALDI-TOF MS requires minimal time for CPO detection with same day turn around. Procedures are also relatively simple and high-level training is not required. Establishing standard procedures and interpretations will be necessary for clinical use.